Gilead Sciences Announces Executive and Board Changes

Ticker: GILD · Form: 8-K · Filed: 2025-03-12T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-of-directors, executive-compensation

Related Tickers: GILD

TL;DR

Gilead's board and exec team are shuffling, effective March 12th.

AI Summary

Gilead Sciences, Inc. announced on March 9, 2025, changes in its executive team and board of directors. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. These changes are effective as of March 12, 2025.

Why It Matters

Changes in executive leadership and board composition can signal shifts in company strategy, operational focus, or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

GILEAD SCIENCES, INC. (company) — Registrant
March 9, 2025 (date) — Date of earliest event reported
March 12, 2025 (date) — Date as of change
Delaware (jurisdiction) — State of Incorporation
333 Lakeside Drive, Foster City, California 94404 (address) — Principal Executive Offices

FAQ

What specific roles have seen departures or appointments within Gilead Sciences?

The filing indicates the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for certain officers, though specific names and roles are not detailed in this summary.

When are these reported changes effective?

The changes reported in this Form 8-K are effective as of March 12, 2025.

What is the primary reason for this 8-K filing?

This 8-K filing is primarily to report the departure of directors or certain officers, the election of directors, and updates to compensatory arrangements of certain officers.

Where are Gilead Sciences' principal executive offices located?

Gilead Sciences' principal executive offices are located at 333 Lakeside Drive, Foster City, California 94404.

What is the Commission File Number for Gilead Sciences?

The Commission File Number for Gilead Sciences is 0-19731.

From the Filing

0001104659-25-023012.txt : 20250312 0001104659-25-023012.hdr.sgml : 20250312 20250312170535 ACCESSION NUMBER: 0001104659-25-023012 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250309 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250312 DATE AS OF CHANGE: 20250312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 25732574 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 tm258955d1_8k.htm FORM 8-K false 0000882095 0000882095 2025-03-09 2025-03-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 9, 2025       GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter)       Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)   333 Lakeside Drive , Foster City , California (Address of Principal Executive Offices)   94404 (Zip Code)   650 - 574-3000 (Registrant’s Telephone Number, Including Area Code)       Not Applicable (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class:   Trading Symbol(s)   Name of Each Exchange on Which Registered Common Stock, par value, $0.001 per share   GILD   The Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On March 12, 2025, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that S